GT Medical Technologies, a 2018 Rosenman Innovator and MTVP-backed company, has secured $37 million in Series D funding to expand the U.S. availability of GammaTile Therapy, a surgically implanted radiation treatment designed to improve outcomes for patients with operable brain tumors. The funding will support commercial growth, clinical adoption, and further research to advance brain tumor treatment.

From the press release:

“Since 2019, doctors across the country have chosen GammaTile as a proven treatment for patients with operable brain tumors,” said Per Langoe, Chief Executive Officer at GT MedTech. “With the support of Evidity and Accelmed, we are well-positioned to expand the availability of GammaTile and advance our ongoing clinical studies to continue transforming brain tumor treatment.”

By delivering tile-based radiation therapy directly into the surgical cavity at the time of tumor removal, GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are at their lowest levels to help prevent regrowth while minimizing radiation exposure to healthy brain tissue.

“The Series D financing round underscores the confidence investors have in GammaTile Therapy and our vision to innovate brain tumor care,” added Sandeep Yadav, Chief Financial Officer of GT MedTech.